(Q35113354)

English

Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

based on heuristic

inferred from title

author name string

Johan Vansteenkiste

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jean Vandebroek

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Kris Nackaerts

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Christophe Dooms

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Dany Galdermans

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Lionel Bosquée

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Alain Delobbe

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Koen Deschepper

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Wim Van Kerckhoven

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Kurt Vandeurzen

10

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Rene Deman

11

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jean Pierre D'Odemont

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Luc Siemons

13

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Paul Van den Brande

14

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Nancy Dams

15

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Leuven Lung Cancer Group

16

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

1 May 2003

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

191-199

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study G

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900515-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0169-5002(02)00515-9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35113354&oldid=1979738451"